KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Acadia Pharmaceuticals (ACAD) Accumulated Depreciation & Amortization: 2011-2024

  • Acadia Pharmaceuticals' Accumulated Depreciation & Amortization rose 6.92% to $10.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $34.1 million, marking a year-over-year increase of 22.56%. This contributed to the annual value of $10.2 million for FY2024, which is 6.92% up from last year.
  • As of Q4 2024, Acadia Pharmaceuticals' Accumulated Depreciation & Amortization stood at $10.2 million, which was up 6.92% from $9.6 million recorded in Q4 2023.
  • Acadia Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $10.2 million for Q4 2024, and its period low was $3.9 million during Q4 2020.
  • Over the past 3 years, Acadia Pharmaceuticals' median Accumulated Depreciation & Amortization value was $9.6 million (recorded in 2023), while the average stood at $9.3 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first decreased by 25.96% in 2020, then surged by 56.64% in 2021.
  • Over the past 5 years, Acadia Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $3.9 million in 2020, then soared by 56.64% to $6.2 million in 2021, then spiked by 30.93% to $8.1 million in 2022, then increased by 18.02% to $9.6 million in 2023, then increased by 6.92% to $10.2 million in 2024.
  • Its Accumulated Depreciation & Amortization stands at $10.2 million for Q4 2024, versus $9.6 million for Q4 2023 and $8.1 million for Q4 2022.